General
Preferred name
dorzolamide
Synonyms
L671152 ()
MK507 ()
MK507 hydrochloride ()
L671152 hydrochloride ()
MK-507 (L-671152) HCl ()
Dorzolamide HCl ()
DORZOLAMIDE HYDROCHLORIDE ()
Dorzolamide (hydrochloride) ()
MK-507 ()
Cosopt Pf ()
Dorzolamide (as hydrochloride) ()
Trusopt ()
Dorzolamide hydrochloride component of cosopt ()
Dorzant ()
Dorzolamida ()
Dorzolamide, trans-(-)- ()
Dorzolamide-d5 (hydrochloride) ()
P&D ID
PD009676
CAS
120279-96-1
130693-82-2
2749856-75-3
Tags
available
drug
Approved by
FDA
First approval
1994
Drug indication
Open-angle glaucoma
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1].
DESCRIPTION
Marketed formulations may contain dorzolamide hydrochloride (PubChem CID 6918132).
(GtoPdb)
DESCRIPTION
Dorzolamide is a carbonic anhydrase inhibitor. It is used to treat high intraocular pressure in ocular hypertension and open angle glaucoma.
(Enamine Bioactive Compounds)
DESCRIPTION
Dorzolamide hydrochloride (MK507 hydrochloride) is the hydrochloride salt form of dorzolamide, an inhibitor of carbonic anhydrase, a zinc-containing enzyme that catalyzes the rapid conversion of carbon dioxide and water into carbonic acid, protons and bicarbonate ions. Distributed throughout many cells and tissues, various carbonic anhydrases play important roles in mineral and metabolic homeostasis.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
2
Compound Sets
25
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
444
Molecular Weight
324.03
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
0.61
TPSA
106.33
Fraction CSP3
0.6
Chiral centers
2.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Carbonic Anhydrase
Carbonic anhydrase I
Carbonic anhydrase II
Carbonic anhydrase IV
CA1, CA12, CA14, CA2, CA4, CA7
Pathway
Metabolic Enzyme/Protease
Metabolism
MOA
Carbonic anhydrase inhibitor
Carbonic Anhydrase Type II Inhibitors
Member status
member
Indication
intraocular pressure, glaucoma
Therapeutic Class
Antihypertensive Agents
Source data

